KR20160058989A - Composition of anti-obesity containing extract of zanthoxylum schinifolium and method of making the same - Google Patents
Composition of anti-obesity containing extract of zanthoxylum schinifolium and method of making the same Download PDFInfo
- Publication number
- KR20160058989A KR20160058989A KR1020140153556A KR20140153556A KR20160058989A KR 20160058989 A KR20160058989 A KR 20160058989A KR 1020140153556 A KR1020140153556 A KR 1020140153556A KR 20140153556 A KR20140153556 A KR 20140153556A KR 20160058989 A KR20160058989 A KR 20160058989A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- obesity
- composition
- acidulant
- sancho
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 109
- 230000003579 anti-obesity Effects 0.000 title claims abstract description 84
- 239000000203 mixture Substances 0.000 title claims abstract description 58
- 241001079064 Zanthoxylum schinifolium Species 0.000 title claims abstract description 9
- 238000004519 manufacturing process Methods 0.000 title claims description 8
- 230000000694 effects Effects 0.000 claims abstract description 57
- 210000001789 adipocyte Anatomy 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 18
- 210000004027 cell Anatomy 0.000 claims description 35
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 18
- 239000002243 precursor Substances 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 12
- 235000013305 food Nutrition 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 7
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 235000021028 berry Nutrition 0.000 claims description 3
- 230000002378 acidificating effect Effects 0.000 claims 1
- 230000004069 differentiation Effects 0.000 abstract description 33
- 230000019491 signal transduction Effects 0.000 abstract description 4
- 230000000903 blocking effect Effects 0.000 abstract description 2
- 239000000469 ethanolic extract Substances 0.000 description 18
- 208000008589 Obesity Diseases 0.000 description 16
- 235000020824 obesity Nutrition 0.000 description 16
- 102000040945 Transcription factor Human genes 0.000 description 9
- 108091023040 Transcription factor Proteins 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 9
- 230000002293 adipogenic effect Effects 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 235000019634 flavors Nutrition 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 230000003078 antioxidant effect Effects 0.000 description 6
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 5
- 108091007960 PI3Ks Proteins 0.000 description 5
- 102000000536 PPAR gamma Human genes 0.000 description 5
- 108010016731 PPAR gamma Proteins 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000011435 rock Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 231100000002 MTT assay Toxicity 0.000 description 4
- 238000000134 MTT assay Methods 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000011759 adipose tissue development Effects 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- 210000003630 histaminocyte Anatomy 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000004410 anthocyanin Substances 0.000 description 3
- 235000010208 anthocyanin Nutrition 0.000 description 3
- 229930002877 anthocyanin Natural products 0.000 description 3
- 150000004636 anthocyanins Chemical class 0.000 description 3
- 235000013527 bean curd Nutrition 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 229940002552 xenical Drugs 0.000 description 3
- 240000006439 Aspergillus oryzae Species 0.000 description 2
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241001466548 Myelophycus simplex Species 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 240000009188 Phyllostachys vivax Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 244000300264 Spinacia oleracea Species 0.000 description 2
- 235000009337 Spinacia oleracea Nutrition 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 102000034337 acetylcholine receptors Human genes 0.000 description 2
- 108020000715 acetylcholine receptors Proteins 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000005265 energy consumption Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 231100001083 no cytotoxicity Toxicity 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- QGZCUOLOTMJILH-UHFFFAOYSA-N 2h-tetrazol-2-ium;bromide Chemical class [Br-].C1=N[NH+]=NN1 QGZCUOLOTMJILH-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000349 Acanthosis Diseases 0.000 description 1
- 208000020154 Acnes Diseases 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000011690 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 240000007185 Albizia julibrissin Species 0.000 description 1
- 241000383638 Allium nigrum Species 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000058061 Glucose Transporter Type 4 Human genes 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- 239000012741 Laemmli sample buffer Substances 0.000 description 1
- 240000000599 Lentinula edodes Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241001257583 Microphyllum Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 244000302909 Piper aduncum Species 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 240000007332 Podocarpus macrophyllus Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 108091006300 SLC2A4 Proteins 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000390 anti-adipogenic effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000013542 behavioral therapy Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000010482 emotional regulation Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012907 medicinal substance Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 238000005554 pickling Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000003893 regulation of appetite Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/40—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by drying or kilning; Subsequent reconstitution
- A23L3/44—Freeze-drying
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/758—Zanthoxylum, e.g. pricklyash
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Medical Informatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
The present invention relates to a sancho extract. More particularly, the present invention provides an acidulant extract that can block the signal transduction pathway of adipocytes and inhibit cell differentiation, thereby exhibiting an anti-obesity effect with few side effects, and a method for producing the acidulant extract.
Obesity is a phenomenon in which excess energy is accumulated in body fat due to an imbalance between the energy consumed by food and the energy consumed by physical activity. Generally, obesity means excessive fat tissue in the body. If such obesity persists for a long time, various metabolic diseases such as diabetes, hyperlipemia, heart disease, stroke, arteriosclerosis, fatty liver and adult diseases are induced. Due to excessive caloric intake and lack of exercise, the obesity population is rapidly increasing not only in developed countries but also in Korea, which is becoming a serious social problem.
Obesity is known to be the main cause of excess energy supply, which is caused by the accumulation of fat in the body by inducing an increase in fat cell size and number. In addition, genetic factors, environmental factors by Westernized diet, psychological factors, It is known that various causes such as abnormalities are acting.
There is a multidisciplinary study on the development of obesity drugs worldwide. Drugs for the treatment of obesity can be broadly divided into the inhibition of fat absorption, the promotion of fat decomposition and heat generation, the regulation of appetite and satiety, the inhibition of protein metabolism, and the emotional regulation associated with the ingestion of food. Typical treatments for obesity include Xenical ™, which inhibits fat absorption with orlistat, and Reductil ™, which stimulates the sympathetic nervous system to sibutramine.
However, Xenical ™ has been reported to have adverse effects such as nausea, abdominal pain, vomiting, itching, and liver damage. Reductin ™ has serious side effects such as headache, anorexia, insomnia and constipation as well as serious cardiovascular side effects There has been controversy such as the recent use standard being strengthened. In addition to pharmacotherapy through these obesity drugs, there are also dietary therapies to limit the intake of foods and exercises to increase energy consumption, psychotherapy, behavioral therapy, and surgical therapy.
The preferred method of treating obesity is to promote energy consumption through exercise and to treat obesity drugs with few side effects as the most safe and effective method. However, in the case of obesity treatment drugs, severe side effects such as the above examples of Xenical ™ and Reductil ™ have been reported, and there is no clear reliance on safety.
Therefore, it is required to develop a substance which shows excellent efficacy of anti-obesity against the human body while ensuring 100% safety. Recently, various studies have been made on substances for treating obesity through in vivo fat burning / degradation mechanism and energy metabolism promotion mechanism, and in particular, functional foods based on a material capable of ensuring safety to human body And so on.
Therefore, anti-obesity compositions based on natural extracts having few side effects have attracted attention, and various studies related thereto have been conducted.
In the related art, Prior Art 1 (KR 10-2011-0127454 A, published on Nov. 25, 2011) discloses that an effective ingredient of corn beard extract, shiitake mushroom extract, The present invention relates to a composition for anti-obesity characterized by an increase in body weight due to ingestion, an increase in weight of liver tissue and epididymal adipose tissue, an increase in total cholesterol concentration in plasma, an increase in triglyceride and glucose concentration, Inhibiting the increase of the amount of the antioxidant effect, thereby exhibiting a substantial antiobestic effect.
Background Art [0002] Prior art 2 (KR 10-2012-0090514A, public date: August 17, 2012) discloses a method of freeze-drying powder or extract of at least one of spinach freeze-dried powder or extract, anthocyanin extract of purplish sweet potato pigment or black garlic The present invention discloses a composition comprising an antioxidant and an anti-obesity composition including a spinach powder or an extract, which comprises a freeze-dried powder, an extract, and a green tea extract powder or extract.
However, research on a wide variety of natural products is needed to develop a composition for anti-obesity that has high anti-obesity effect and no side effects.
The object of the present invention is to provide a method for preventing or inhibiting obesity by inhibiting the differentiation of mast cells by blocking the signal transduction pathway of mast cells and thus being able to exhibit an anti-obesity effect, and by using an extract utilizing natural resources, And an anti-obesity composition for providing an anti-obesity sancho extract.
Another object of the present invention is to provide a method for producing the above-described antioxidant acidolide extract.
In order to achieve the above object, the composition for anti-obesity comprising an acid-fast bacillus extract according to an embodiment of the present invention may contain Zanthoxylum schinifolium and may have an anti-obesity effect.
The sancho extract may be extracted from water, any one selected from the group consisting of alcohols having 1 to 10 carbon atoms, hexane, chloroform, ethyl acetate, and mixtures thereof.
The sancho extract may be a sancho leaf extract.
And the amount of the acidulant extract is 0.01 to 30% by weight.
The anti-obesity composition containing the sancho extract may have a viscosity of 1.2 to 100 cP.
The AChE extract may inhibit the differentiation of 3T3-L1 adipose precursor cells into adipocytes.
The food composition according to another embodiment of the present invention may include an anti-obesity composition containing the above-described ACE extract.
The pharmaceutical composition according to another embodiment of the present invention may include an anti-obesity composition containing the above-described ACE extract.
A method for preparing an anti-obesity composition comprising an acidulant extract according to another embodiment of the present invention comprises: drying an acidulant; Any one selected from the group consisting of hydrogen peroxide and water, the alcohol having 1 to 10 carbon atoms, hexane, chloroform, ethyl acetate, and a mixture thereof is mixed at a weight ratio of 1:10 to 10: 1, An extracting step of extracting; And concentrating the extract obtained through the extraction step at 35 to 65 DEG C, and lyophilizing the concentrated extract to powder the powdered acanthoxylum extract, wherein the anti-obesity effect Lt; / RTI >
Hereinafter, the present invention will be described in more detail.
The composition for anti-obesity comprising an acidulant extract according to an embodiment of the present invention may include Zanthoxylum schinifolium and may have an anti-obesity effect.
Sancho is common in mountainous areas, 3 m in height, twigs are spiny and reddish brown. Leaves are alternate phyllotaxis of 13 ~ 21 small leaves. The small leaves are 1 ~ 5cm wide, narrow, with narrow ends, wavy sawtooth on the edge, and a transparent point of oil. It is also called a sancho wood.
Flowers are dioecious, bloom in August-September, white, hanging on the end of the branch with the flower buds. Small peduncle has nodule, Calyx is divided into 5 pieces, and the split piece is egg-shaped circle. 5 petals, 2mm long and bend inward. The stamen is the same length as the petal, and the pistil is divided into 3 pieces.
The fruit is capillary, round, 4mm long and greenish brown. When ripened, it divides into 3 pieces and black seeds appear. The fruit is picked before harvest and the oil is sown in the ripe seed. In one room, the fruit skin is used as a medicinal substance called wild pepper. It removes the abdominal coldness, stops vomiting and diarrhea, and is effective in roundworms, glanditis, toothache and seborrheic dermatitis. It is distributed in Korea, Japan, and China.
It is similar to early-flowering tree, but has one thorn on the bottom of the petiole, and its fruit is greenish brown with petals. It is called "var. Inermis", which has no thorns, "var. Subinermis", which is short in length, oval or oval, and var. Microphyllum, whose leaves are narrow and small. .
The anti-obesity effect inhibits the differentiation of adipocytes, promotes lipolysis and absorption, inhibits amylase activity, inhibits glucosidase activity, inhibits lipase activity, promotes activity of ediportin, And the like.
The sancho extract may be prepared by inoculating one or more microorganisms, such as Bacillus lichenifomis or Aspergillus oryzae, on the leaves of Sanchos.
When the fermented sancho leaf fermented according to the fermentation process by the microbial inoculation is used as an extract of the sancho extract, the effective ingredient of the anti-obesity activity is increased and the anti-obesity effect can be further enhanced.
The at least one microorganism among the Bacillus lichenifomis or Aspergillus oryzae may be inoculated in an amount of 0.0001 to 0.05% (w / v) relative to the mass of the dried cod leaf.
The sancho extract may be extracted from water, any one selected from the group consisting of alcohols having 1 to 10 carbon atoms, hexane, chloroform, ethyl acetate, and mixtures thereof.
Preferably, the extract may be an alcohol extract having 1 to 10 carbon atoms, and the acid and the alcohol having 1 to 10 carbon atoms may be mixed in a weight ratio of 1:10 to 10: 1. When the alcohol is used, it is useful for extracting an active ingredient of an anti-obesity. When the alcohol is used, it may be suitable for extracting an active ingredient of an anti-obesity contained in the acnes.
More preferably, the acid and the alcohol having 1 to 10 carbon atoms may be mixed in a weight ratio of 1:10 to 1: 1. By the above-mentioned range, the yield of the anti-obesity effective ingredient contained in the acacia var.
The sancho extract may be a sancho leaf extract. When the sancho leaf is used, an anti-obesity ingredient having an excellent effect can be obtained as compared with the case of using anthocyanins or stem.
It may preferably be the progeny of anthocyanins used for the acidulant extract. It is advantageous in that it can be taken for a long time as an anti-obesity product because it has a very high anti-obesity effect and a good flavor. The shrimp may be six to twelve months old. The reason for this is that, although not limited thereto, the anti-obesity effect and high flavor can be kept high when the above-mentioned range is used.
The composition for anti-obesity comprising the acanthoxylum extract may further comprise a rock beard extract for the acantholyticum extract. When the bean curd extract is further added, the anti-obesity effect can be more excellent, and the flavor is excellent, so that it is possible to have a more excellent effect in utilization of food composition and the like.
The rock beard is Myelophycus Simplex Papenfuss and the name of the rock beard is Myelophycus Simplex Papenfuss. It belongs to the broad seaweed family. It is a brownish or blackish brown needles and several bundles are formed. The size is 5 ~ 15 cm in height and 1 ~ 2 mm in thickness. The lower part is thinner and shorter.
The composition for anti-obesity may be prepared by mixing dry soybean curd and rock beard at a weight ratio of 1:10 to 10: 1 and extracting with water or alcohol, and preferably the alcohol is ethanol. By the above range, the anti-obesity effect can be more excellent.
Preferably, the composition for anti-obesity may be a mixture of dried soybean curd and rock beard at a weight ratio of 2: 3 to 4: 5. By the above range, the flavor can be excellent and the anti-obesity effect can be higher. The composition for anti-obesity according to the above-mentioned range was tested according to the same method in the following Experimental Examples. As a result, the effect of inhibiting the differentiation of 3T3-L1 cells was 2.4 to 3.1 times higher than that of dried shampoos at the same concentration range, Were almost the same.
And the amount of the acidulant extract is 0.01 to 30% by weight.
And the amount of the acidulant extract is 0.01 to 30% by weight. When the amount of the AChE extract is less than 0.01% by weight, the anti-obesity effect of the AChE extract is lowered. When the AChE extract is contained in an amount exceeding 30% by weight, the anti-obesity effect is not increased, Therefore, the above range may be suitable for use as a composition exhibiting a high anti-obesity effect without side effects according to the present invention.
And preferably 0.1 to 5% by weight of the acanthoxylum extract. This means that the anti-obesity effective substance contained in the above-mentioned ACS extract may have an excellent anti-obesity effect within the above range.
Further, more preferably, the acid pickling extract may be contained in an amount of 0.1 to 0.5% by weight. By the above-mentioned range, a high anti-obesity effect can be obtained without side effects. In particular, the above range has an advantage of exhibiting an excellent anti-obesity effect even in a relatively small concentration range.
The anti-obesity composition containing the sancho extract may have a viscosity of 1.2 to 100 cP.
According to the viscosity range, it can be used as a food composition or other preference food in which a unique flavor possessed by the sancho leaf can be felt and a high flavor and texture can be provided. That is, the composition for anti-obesity containing the acanthoxylum extract should have a high texture and flavor for the continuous administration of the composition for anti-obesity.
In order to adjust the viscosity, the composition for anti-obesity comprising the acanthoxylum extract may further comprise a thickening agent. The thickening agent is considered to be a food or pharmacologically acceptable thickening agent that can be used by those skilled in the art.
Preferably, the composition for anti-obesity comprising the sancho extract may have a viscosity of 1.2 to 10 cP. According to the above range, the texture and flavor are very good, which can be helpful for steady consumption for a certain period of time.
The AChE extract may inhibit the differentiation of 3T3-L1 adipose precursor cells into adipocytes.
The ACS extract has a high anti-obesity effect because it exerts an excellent effect of inhibiting the differentiation of 3T3-L1 adipose precursor cells into adipocytes.
The food composition according to another embodiment of the present invention may include an anti-obesity composition containing the above-described ACE extract.
The pharmaceutical composition according to another embodiment of the present invention may include an anti-obesity composition containing the above-described ACE extract. The pharmaceutical composition may include a composition for anti-obesity containing the above-mentioned acanthoxylum extract in a pharmaceutically acceptable range.
A method for preparing an anti-obesity composition comprising an acidulant extract according to another embodiment of the present invention comprises: drying an acidulant; Any one selected from the group consisting of hydrogen peroxide and water, the alcohol having 1 to 10 carbon atoms, hexane, chloroform, ethyl acetate, and a mixture thereof is mixed at a weight ratio of 1:10 to 10: 1, An extracting step of extracting; And concentrating the extract obtained through the extraction step at 35 to 65 DEG C, and lyophilizing the concentrated extract to powder the powdered acanthoxylum extract, wherein the anti-obesity effect Lt; / RTI >
Preferably, the extracting step is repeated two to five times with respect to the extract obtained through the extraction step between the extraction step and the pulverization step. The above-mentioned repeated extraction step has an advantage that a large amount of active ingredient can be obtained without dilution of concentration.
When the extraction step of extracting at 10 to 35 캜 and the concentration step of concentrating at 35 to 65 캜 according to the method for producing an acidulant extract of the present invention, the effective substance against the anti-obesity contained in the acid plant is not destroyed, ≪ / RTI >
The composition for anti-obesity including an acidulant extract according to an embodiment of the present invention includes an acidulant extract to block the signal transduction pathway of mast cells to inhibit the differentiation of the mast cell, thereby preventing or inhibiting obesity, And it has no side effect of the human body by utilizing extracts utilizing natural resources. The above-described composition for anti-obesity can be used to make an anti-obesity functional product in various product fields such as anti-obesity plant additives.
The method for preparing an anti-obesity composition comprising an acid-fast berry extract according to another embodiment of the present invention provides a method for preparing an anti-obesity composition comprising an acid-fast berry extract having the anti-obesity effect.
FIG. 1 relates to the effect of an antiobesity composition containing an acidulant extract on the 3T3-L1 cell survival rate according to an embodiment of the present invention.
FIG. 2 is a graph showing the effect of the acidulant extract on inhibition of differentiation of 3T3-L1 cells according to an embodiment of the present invention.
FIG. 3 is a graph showing the effect of the AChR extract on inhibition of differentiation of 3T3-L1 cells according to an embodiment of the present invention.
FIG. 4 relates to how an acidolytic extract according to an embodiment of the present invention affects the expression of adipogenic transcription factors.
FIG. 5 relates to how an acidolytic extract according to an embodiment of the present invention affects the expression of adipogenic transcription factors.
FIG. 6 relates to how an acanthosis extract according to an embodiment of the present invention affects the expression of adipogenic transcription factors.
FIG. 7 relates to how an acidulant extract according to an embodiment of the present invention affects the expression of adipogenic transcription factors.
FIG. 8 relates to how an acidolytic extract according to an embodiment of the present invention affects the expression of adipogenic transcription factors.
Hereinafter, embodiments of the present invention will be described in detail so that those skilled in the art can easily carry out the present invention. The present invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein.
[Preparation Example: Preparation of an Acanthopanax extract]
Asanosperm dough was inoculated on a common sickle leaf, a sickle leaf collected from a sprout, and an aspergillus dorsiflexifolia leaf, and the fermented sourdough was dried, pulverized to be a fine powder, and dipped in ethanol for 10 to 50 hours (EEZS) was obtained according to the method for preparing an anti-obesity composition containing the above-described AChE extract while maintaining the temperature at 25 to 32 ° C.
[Experimental Example: Cytotoxicity and anti-obesity effect test]
1. Experimental material
The PPARγ, C / EBPα, C / EBPβ and actin antibodies used for protein analysis in this experiment were obtained from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA) and Cell Signaling Technology (Beverly, MA, USA). Peroxidase-labeled donkey anti-rabbit and peroxidase-labeled sheep anti-mouse immunoglobulin used as secondary antibodies for immunoblotting were purchased from Amersham Life Science Corp. (Arlington Heights, Ill., USA). In addition, insulin, dexamethasone, and IBMX used to differentiate 3T3-L1 adipose precursor cells and Oil Red O used to identify triglyceride production in adipocytes were purchased from Sigma-Aldrich (St. Louis, MO, USA).
2. Cell culture
The 3T3-L1 adipose precursor cells used in the experiments were obtained from the ATCC (American Type Culture Collection, Manassas, VA, USA).
The 3T3-L1 adipose precursor cells were cultured at 37 ° C under 5% CO 2 in Dulbecco's Modified EaDCRT Media (DMEM, Gibco-BRL, Grand Island, NY, USA), 10% bovine calf serum (BCS, Gibco BRL ) And 1% penicillin and streptomycin (Gibco BRL) at 37 ° C and 5% CO 2 . FBS was dissolved at room temperature to inactivate remaining complement components and then heat inactivation (heating in a 50 ° C water bath for 30 minutes). In order to overcome the overcorrection caused by cell proliferation, the growth medium was exchanged every 48 hours to maintain a proper number of cells.
3. MTT assay
MTT assays were performed to determine the range of concentrations to be used in the experiments as well as the cytotoxicity of each substance. 3T3-L1 adipose precursor cells were seeded in 6 well plates for cell culture and cultured to confluent state. MSME was treated at 100, 300 and 500 μg / ml concentration. After 72 hours, 200 μl of tetrazolium bromide salt (MTT, Amresco, Solon, OH, USA) diluted at a concentration of 0.5 mg / ml was added and cultured in a CO2incubator for 2 hours. Then, the medium and the MTT reagent were cleanly removed. DMSO was dispensed in 1 ml aliquots. All of the generated formazan was dissolved in 200 μl aliquots in a 96-well plate. Absorbance was measured at 540 nm using an ELISA reader (Molecular Devices, Sunnyvale, CA, USA). The toxicity of each cell was determined by the average absorbance value of each control and expressed as a percentage of the average absorbance value.
4. induction of adipocyte differentiation
3T3-L1 adipose precursor cells were cultured in confluent 6-well plates to confluent and then replaced with differentiation medium containing 10 μg / ml insulin, 10 μM dexamethasone and 0.5 mM 3-isobutyl-1-methylxanthine (IBMX) Induced differentiation of lipid precursor cells. After 2 days of induction of differentiation, the cells were replaced with medium containing 10 μg / ml insulin every 2 days to promote the differentiation of adipose precursor cells. To confirm the effect of MSME in the course of adipogenesis, MSME was treated together at the beginning of differentiation.
5. Oil Red O staining
Oil Red O staining was performed to confirm the content of fat formed during lipid progenitor cell differentiation. The prepared 3T3-L1 adipose precursor cells were washed with PBS, fixed with 3.7% formalin for 10 minutes, washed with 60% isopropanol, treated with Oil Red O solution, and stained at room temperature for 20 minutes. After dyeing, Oil Red O solution was removed and washed 4 times with PBS. The stained cells were observed using a phase contrast microscope. For quantitative analysis after oil red O staining, fat was extracted with 100% isopropanol, and transferred to a 96-well plate in 200 μl increments. Absorbance was measured at 500 nm using an ELISA reader and expressed as a percentage of the absorbance value of the control group.
6. Western blot analysis
To the 3T3-L1 adipose precursor cells prepared in the same manner, an appropriate amount of lysis buffer (25 mM Tris-Cl (pH 7.5), 250 mM NaCl, 5 mM EDTA, 1% NP-40, 1 mM phenymethylsulfonyl fluoride dithiothreitol (DTT)] was added, reacted at 4 ° C for 1 hour, and centrifuged at 14,000 rpm for 30 minutes to isolate the total protein in the supernatant. The protein concentration of the supernatant was quantitated according to the Bio-Rad protein assay reagent (Bio-Rad, Hercules, Calif., USA) and the method of use, and then mixed with an equal volume of Laemmli sample buffer (Bio-Rad). Samples of the same amount were separated by electrophoresis using sodium dodecyl sulphate (SDS) -polyacrylamide gel and electroblotted with PVDF membrane (Bio-Rad, USA). The PVDF membrane was treated with 5% skim milk to block non-specific proteins, and the primary antibody was treated for 2 hours at room temperature or over night at 4 ° C., and washed with PBS-T (4 times for 10 minutes) and reacted for 1 hour at room temperature using a secondary antibody (diluted 1: 1000 with PBS-T) that corresponds to the treated primary antibody. After the reaction was completed, the Enhanced Chemiluminoesence (ECL) solution (Amersham Life Science Corp.) was applied to the dark room and then exposed to X-ray film to analyze the amount of specific protein expressed.
7. Statistical analysis
All the results were expressed as mean ± standard deviation (SD) using Statistical Package for the Social Sciences (SPSS) statistical program. Statistical significance of the analytical items was verified at the p <0.05 level using Student t-test and Duncan's multiple range test.
[Experimental result: cytotoxicity and anti-obesity effect test]
1. Effect of ethanol extract of Sancho leaf on 3T3-L1 cell survival
To investigate the cytotoxicity of ethanol extracts of Sanchospora leaves on 3T3-L1 adipocytes, MTT assay experiments were carried out at a concentration of 100 to 700 μg / ml. When the ethanol extracts of P. vivax were treated, the degree of cell proliferation was calculated as a percentage of that of the control, and the ethanol extract of the P. vivax showed cytotoxicity. The results of MTT assay for the effect of ethanol extract on the growth of 3T3-L1 cells were shown in Fig. At the concentration of 200 μg / ml, there was almost no cytotoxicity. Therefore, additional experiments were carried out at concentrations of 10, 50, 150, and 200200 μg / ml, which were confirmed to have no cytotoxicity (see FIG. 1 below). The same results were obtained with the ethanol extract of the fermented sancho leaf.
2. Effect of ethanol extract of Sanchospora japonica on the inhibition of differentiation of 3T3-L1 cells
To elucidate the effects of ethanol extracts on the lipid differentiation and triglyceride accumulation of lipid precursor cells, ethanol extracts of P. chinensis were treated with appropriate concentrations to induce differentiation into lipid precursor cells into mature adipocytes. After induction of differentiation, differentiation was made before and after dyeing with Oil Red O and the degree of lipogenesis was observed with a phase contrast microscope. The results are shown in Fig. 2 below.
2, when the differentiation was induced without treatment of the ethanol extract of the sancho leaf, in contrast to the control without induction of differentiation, it was observed that the formation of lipids in the cytoplasm was actively induced, and the ethanol extract of the sancho leaf And that the formation of lipid sphere was inhibited by treatment concentration.
In addition, it was confirmed that when the ethanol extract of the sancho leaf was not treated and the differentiation was induced, the amount of the neutral fat was inhibited by the ethanol extract of the sancho leaf in a concentration-dependent manner. Respectively.
Therefore, referring to FIG. 3, it can be confirmed that the ethanol extract of Sancho leaf has an excellent effect on the inhibition of differentiation into adipocytes in 3T3-L1 adipose precursor cells. In addition, the same test was conducted on the basis of the ethanol extract of the fermented sancho leaf. As a result, it was confirmed that the amount of triglyceride was decreased in the same manner as the ethanol extract of the sancho leaf, It was confirmed that the extract had a better effect of inhibiting the differentiation of 3T3-L1 cells, about 5%, compared with the non-fermented ethanol extract of common leaf of Sancho.
The adipogenesis process, which is differentiated from adipocyte precursor cells into adipocytes, involves a number of adipogenic transcription factors. C / EBPα is a major transcription factor that regulates C / EBPα and PPARγ. PPARγ and C / EBPα are key transcription factors that regulate adipogenesis. They are highly expressed in the late phase of differentiation and are a terminal marker of adipogenesis including adiponectin and GLUT4 Lt; RTI ID = 0.0 > expression < / RTI > These differentiated cells have characteristic features of adipocytes by inducing specific gene expression along with morphological features such as lipid droplet generation and cell size increase. Therefore, it was confirmed at the protein level how the AChR extract affects the expression of adipogenic transcription factors.
As shown in FIG. 4, when the differentiation inducing factors insulin, dexamethasone and IBMX were treated to induce differentiation, the expression of PPARγ, C / EBPα and C / EBPβ was markedly increased, C / EBPα and C / EBPβ were decreased at the protein level in the treated group with the ACE extract, and the adipogenic transcription factors PPARγ and C / EBPβ in the 3T3-L1 adipocyte precursor cells, EBP? And C / EBP? To inhibit lipid droplet and TG production, thereby inhibiting differentiation into adipocytes.
On the other hand, the anti-adipogenic activity of the ethanol extract of the Sancho leaf is related to the inactivation of the ERK and PI3K / Akt pathway, which are high signal transducers in 3T3-L1 cells. The two mechanisms established in adipocyte differentiation are ERK and PI3K / Akt pathways that play an important role in adipocyte differentiation.
3T3-L1 cells were pretreated with ERK- or PI3K-specific inhibitor for 1 hour and cell culture was performed under MDI treatment with or without 200 μg / mL P. acacia leaf extract. And phosphorylated ERK, PI3K, and Akt were measured at various time intervals after MDI treatment by Western blot.
As shown in FIGS. 5 and 7, the inhibition of ERK and PI3K / Akt pathway by inhibiting the differentiation of adipocytes is effective in preventing, ameliorating, or treating obesity. And it was confirmed that it has an anti-obesity effect.
The results of using positive control as specific inhibitors of ERK- or PI3K- in 3T3-L1 cells are shown in FIGS. 6 and 8 below.
While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the invention is not limited to the disclosed exemplary embodiments, Of the right.
Claims (9)
Which has an anti-obesity effect
An antiobesity composition comprising an acidulant extract.
The acid-extracted extract is obtained by extracting water with any one selected from the group consisting of water, alcohols having 1 to 10 carbon atoms, hexane, chloroform, ethyl acetate, and mixtures thereof
An antiobesity composition comprising an acidulant extract.
The above-mentioned sancho extract is a sancho leaf extract
An antiobesity composition comprising an acidulant extract.
Wherein the acidic extract is contained in an amount of 0.01 to 30% by weight
An antiobesity composition comprising an acidulant extract.
An anti-obesity composition comprising an acidulant extract
And a viscosity of 1.2 to 100 cP
An anti-obesity composition comprising an acidulant extract
The above-
3T3-L1 < / RTI > lipo-precursor cells to differentiate into adipocytes
An antiobesity composition comprising an acidulant extract.
Any one selected from the group consisting of hydrogen peroxide and water, the alcohol having 1 to 10 carbon atoms, hexane, chloroform, ethyl acetate, and a mixture thereof is mixed at a weight ratio of 1:10 to 10: 1, An extracting step of extracting;
A step of concentrating the extract through the extraction step at 35 to 65 DEG C and
And lyophilizing the concentrated extract to powderize the powdered acantholyticum extract,
Which has an anti-obesity effect
A method for producing an anti-obesity composition comprising an acidulant extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140153556A KR20160058989A (en) | 2014-11-06 | 2014-11-06 | Composition of anti-obesity containing extract of zanthoxylum schinifolium and method of making the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140153556A KR20160058989A (en) | 2014-11-06 | 2014-11-06 | Composition of anti-obesity containing extract of zanthoxylum schinifolium and method of making the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20160058989A true KR20160058989A (en) | 2016-05-26 |
Family
ID=56104447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020140153556A KR20160058989A (en) | 2014-11-06 | 2014-11-06 | Composition of anti-obesity containing extract of zanthoxylum schinifolium and method of making the same |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20160058989A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200042311A (en) * | 2018-10-15 | 2020-04-23 | 한국과학기술연구원 | Compositions for for inhibiting of macrophage death by triglycerides comprising extracts of Angelica takeshimana |
| KR20210107302A (en) | 2020-02-24 | 2021-09-01 | 재단법인 경남한방항노화연구원 | Manufacturing Method of a cosmetic composition containing Zanthoxylum schinifolium oil for relieving itching |
-
2014
- 2014-11-06 KR KR1020140153556A patent/KR20160058989A/en not_active Application Discontinuation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200042311A (en) * | 2018-10-15 | 2020-04-23 | 한국과학기술연구원 | Compositions for for inhibiting of macrophage death by triglycerides comprising extracts of Angelica takeshimana |
| KR20210107302A (en) | 2020-02-24 | 2021-09-01 | 재단법인 경남한방항노화연구원 | Manufacturing Method of a cosmetic composition containing Zanthoxylum schinifolium oil for relieving itching |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101651907B1 (en) | Composition for Prevention or Treatment of Obesity Comprising Tenebrio molitor larva extract or Tenebrio molitor larva suspension | |
| KR101566320B1 (en) | Cosmetic composition comprising an Impatiens balsamina L, Maca, Rosa multiflora Thunberg, Eryobotrya japonica and Pachyrrhizus erosus Complex-fermented extract | |
| KR101930483B1 (en) | Smilax china leaf fermented with Aspergillus species and Extract of the same | |
| KR101914344B1 (en) | A moisturizing and anti-wrinkle cosmetic composition comprising fermented barley, fermented pear juice, fermented soybeans and fermented pomegranate extract and the method preparation of thereof | |
| CN106937709A (en) | A kind of natural dog food composition of the bright hair of skin care and preparation method thereof | |
| CN109652271A (en) | A kind of production method of health care Spondias axillaris fruit wine | |
| KR101770036B1 (en) | Composition comprising Schizandrae Fructus extract asan effective component for preventing and treatingarthritis | |
| CN110432428A (en) | Black coarse cereal powder of a kind of Hericium erinaceus five and preparation method thereof | |
| KR20180011021A (en) | Pharmaceutical composition comprising extract of Clematis apiifolia DC. or Silene armeria L. for treating or prventing inflammatory disease | |
| KR20160058989A (en) | Composition of anti-obesity containing extract of zanthoxylum schinifolium and method of making the same | |
| US11096885B2 (en) | Composition for enhancing skin elasticity or improving skin wrinkles comprising ginseng cell lysate | |
| KR20150067597A (en) | Maximowiczia Chinensis Extracts For improvement Of Muscel Antioxidant Activity And Manufacturing Method of thereof | |
| KR20160060834A (en) | Compositions for culture media of Kefir grain comprising plant extract and compositions for improving skin conditions comprising fermented products using the same | |
| KR102249711B1 (en) | Composition for enhancing skin elasticity or improving skin wrinkels comprising enzyme treated extract of leguminous plants cultured root | |
| KR20130005005A (en) | Cosmetic composition and manufacturing process of plant extracts consisting of adansonia digitata, lithospermum erythrorhizon siebold and zuccarini., dioscorea japonica thunberg and nelumbo nucifera gaertner having anti-inflammation and anti-allergic effect | |
| KR20210081298A (en) | Anti-obesity composition and method of preparing the same | |
| KR101602540B1 (en) | Composition of anti-obesity containing extract of myelophycus simplex and method of making the same | |
| KR20210075634A (en) | The composition containing co-fermented ussuri pear extract for the prevention of anti-obesity | |
| KR20160058203A (en) | Composition for Anti-obesity Using an Extract of Rape Flower | |
| KR102141862B1 (en) | Increasing method of cordycepin of Cordyceps millitaris and bioactive compounds of strawberry and Composition for preventing or treating obesity comprising fermented extracts | |
| KR101607109B1 (en) | Composition for preventing or improvement of obesity with fermented Curcuma longa and/or Platycodon grandiflorum, manufacturing method thereof | |
| KR20190044175A (en) | Composition for preventing hair loss and promoting hair growth comprising bean tissue cultured extract and mathod for preparing the same | |
| Guo et al. | Edible Vitalmelon Fruit Extract Inhibits Adipogenesis and Ameliorates High‐Fat Diet‐Induced Obesity | |
| KR20180088947A (en) | Manufacturing method of lotus leaf fermented extract, meat producing stuff having anti-obesity functional using the fermented extract anc meat product thereby | |
| KR102061622B1 (en) | Composition including mori folium extracts for antioxidant activation and anti-inflammatory |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |